Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
Sponsor: University Hospital, Clermont-Ferrand
Summary
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.
Key Details
Gender
All
Age Range
18 Years - 50 Years
Study Type
OBSERVATIONAL
Enrollment
144
Start Date
2026-03-05
Completion Date
2028-03
Last Updated
2026-03-09
Healthy Volunteers
No
Conditions
Interventions
Blood collection
Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.
Locations (1)
CHU de Clermont-Ferrand
Clermont-Ferrand, France